fashion -WSS

fashion

author：explore 2025-09-30 20:20:08 - browse：3116

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Stanford president to resign after investigation of research

knowledge

WSS

FDA approves updated Covid vaccines

How dance can help health care workers heal from trauma

Telehealth for opioid use disorder is lifesaving

Medical experts are missing from AI regulatory conversations

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

New Covid vaccine is recommended for everyone 6 months or older

entertainment

fashion

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

What to make of Biden’s latest efforts on cancer research

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Private equity could exacerbate cardiology's overuse problem, experts fear

In Memoriam: Notable people who died in 2023

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

As demand for Covid shots wanes, Moderna seeks its next success

New warning issued for rebooking air travel after delays, cancellations

DIEP, the 'gold standard' of breast reconstruction, is under threat

Telehealth for opioid use disorder is lifesaving

knowledge

Medical experts are missing from AI regulatory conversations

IRA could hurt research into orphan drugs for rare diseases

Regeneron agrees to White House price limits on anti

Private equity could exacerbate cardiology's overuse problem, experts fear

What to make of Biden’s latest efforts on cancer research

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

hotspot

knowledge

focus

Wikipedia